Search

Your search keyword '"Filipowicz Sosnowska, A"' showing total 4 results
Start Over Author "Filipowicz Sosnowska, A" Journal clinical rheumatology
4 results on '"Filipowicz Sosnowska, A"'

2. HLA typing and seropositivity in finnish and in polish patients with rheumatoid arthritis and amyloidosis

Author

B. Maczynska-Rusiniak, Saija Koskimies, Leena Paimela, S. Tiitinen, A. Filipowicz-Sosnowska, K. Lehtinen, K. Kaarela, and Marjatta Leirisalo-Repo

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Human leukocyte antigen, Arthritis, Rheumatoid, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, HLA Antigens, Internal medicine, medicine, Humans, Rheumatoid factor, 030212 general & internal medicine, Finland, Aged, 030203 arthritis & rheumatology, Secondary amyloidosis, business.industry, Amyloidosis, Age Factors, General Medicine, Middle Aged, medicine.disease, 3. Good health, Rheumatoid arthritis, Immunology, Female, Poland, business
Abstract

We determined HLA-A, -B, -C and -DR antigens in 83 patients with rheumatoid arthritis (RA) and reactive secondary amyloidosis (RSA), 60 in Finland and 23 in Poland, and compared the results with control RA patients and blood donors. There were no significant differences in the frequencies of HLA between the RA patients with and those without RSA in either Finland or Poland, and no significant differences between the Finnish and Polish patients with RSA. All the RSA patients from Finland and 70% of the RSA patients from Poland were seropositive. In the development of RSA, the prolonged period of inflammatory stimuli may play a more important role than genetic factors.

Published
1992
Full Text
View/download PDF

3. Nabumetone induces less gastrointestinal mucosal changes than diclofenac retard

Author

V Vlasáková, B. Gömör, Urbanová Z, J Vítová, I Rybár, B Rojkovich, L Green, S Mackiewicz, K Toth, B Siro, Shaul Sukenik, Karel Pavelka, K Bernacka, A Filipowicz-Sosnowska, H Maldyk, Michael Ehrenfeld, R. Becvar, and J Bereczki

Subjects
Adult, medicine.medical_specialty, Diclofenac, Adolescent, Gastrointestinal Diseases, Nabumetone, Population, Osteoarthritis, Gastroenterology, Osteoarthritis, Hip, law.invention, Rheumatology, Randomized controlled trial, law, Internal medicine, medicine, Humans, Endoscopy, Digestive System, Intestinal Mucosa, education, Aged, Pain Measurement, Aged, 80 and over, Gastrointestinal tract, education.field_of_study, business.industry, Stomach, Anti-Inflammatory Agents, Non-Steroidal, General Medicine, Middle Aged, Osteoarthritis, Knee, medicine.disease, Butanones, Surgery, stomatognathic diseases, medicine.anatomical_structure, Treatment Outcome, Gastric Mucosa, Duodenum, Safety, business, medicine.drug
Abstract

The aim of the study was to compare the efficacy and the effects on the mucosa of the gastrointestinal tract (GIT) of nabumetone and diclofenac retard in patients with osteoarthritis (OA). An open, multicentre, randomised, comparative, endoscopy-blind parallel group study included 201 patients with nabumetone and 193 patients with diclofenac retard suffering from moderate to severe OA of the knee or hip joint. Twelve clinical efficacy variables were assessed and a portion of the population underwent gastroduodenoscopy. All patients exhibited significant improvement in pain severity and pain relief (p50.001 and p50.0001, respectively) but there were no differences between the groups for all the efficacy variables. Eleven per cent of patients on nabumetone and 19% on diclofenac experienced GIT side-effects. Sixty-nine patients with nabumetone and 61 with diclofenac underwent gastroduodenoscopy. The differences in the mucosal grade for the oesophagus, stomach and duodenum at baseline were not significant. In the oesophagus there were significantly less changes after treatment with nabumetone (p = 0.007) than with diclofenac; there were similar findings in the stomach (p50.001) but the difference in the duodenum was not significant. This study indicates that nabumetone and diclofenac retard have similar efficacy in the treatment of OA, but nabumetone has significantly fewer GIT side-effects.

Published
1999

Catalog

Books, media, physical & digital resources
See catalog results